Therapeutic | Girentuximab |
Target | CA9 |
Heavy Chain | DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS |
Light Chain | DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb Radiolabelled |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2009 |
INN Year Recommended | 2010 |
Companies Involved | Centocor Inc, Heidelberg Pharma AG |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Renal cancer |
Notes |